-
Joining by phone ONLY:
+1 204 272 7920 Canada
+1 438 809 7799 Canada
+1 587 328 1099 Canada
+1 647 374 4685 Canada
+1 647 558 0588 Canada
+1 778 907 2071 Canada
+1 780 666 0144 Canada
Meeting ID: 986 8740 4228
Find your local number: https://echo.zoom.us/u/kdeYJ8w8oS
Press *6 to mute your line when not speaking
Password: boreal
Session Resources
Robblee, J., Minen, M. T., Friedman, B. W., Cortel-LeBlanc, M. A., Cortel-LeBlanc, A., & Orr, S. L. (2026). 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Headache, 66(1), 53–76. https://doi.org/10.1111/head.70016
https://pubmed.ncbi.nlm.nih.gov/41321235/
Pozo-Rosich, P., Caronna, E., Sacco, S., Peres, M. F. P., Ashina, S., Özge, A., Ahmed, F., Velez-Jimenez, M. K., Jenkins, B., Wang, S. J., Schwedt, T. J., Sakai, F., Levin, M., Burstein, R., Terwindt, G. M., & Tassorelli, C. (2025). Early treatment in migraine - A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society. Cephalalgia : an international journal of headache, 45(10), 3331024251387721. https://doi.org/10.1177/03331024251387721
https://pubmed.ncbi.nlm.nih.gov/41134822/
Medrea, I., Cooper, P., Langman, M., Sandoe, C. H., Amoozegar, F., Hussain, W. M., Bradi, A. C., Dawe, J., Guay, M., Perreault, F., Reid, S., Todd, C., Skidmore, B., & Christie, S. N. (2024). Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1–23. Advance online publication. https://doi.org/10.1017/cjn.2024.285
https://pubmed.ncbi.nlm.nih.gov/39506371/
Medrea, I., Cooper, P., Lagman-Bartolome, A. M., Sandoe, C. H., Amoozegar, F., Hussain, W. M., Bradi, A. C., Dawe, J., Guay, M., Perreault, F., Reid, S., Todd, C., Skidmore, B., & Christie, S. N. (2025). Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis - CORRIGENDUM. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1. Advance online publication. https://doi.org/10.1017/cjn.2025.10381
https://pubmed.ncbi.nlm.nih.gov/40842385/
Øie, L. R., Wergeland, T., Salvesen, Ø., Gravdahl, G. R. B., Aschehoug, I., Gulati, S., Bj Rk, M. H., Lundqvist, C., Alstadhaug, K. B. R., Winsvold, B. S., Aamodt, A. H., Larsen, I. C., B E, M. G., Braschinsky, M., Müller, B., Vetvik, K. G. T., Müller, K. I., Aaseth, K., Khanevski, A. N., Øvrevik, A. B., … Tronvik, E. (2025). Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. The Lancet. Neurology, 24(10), 817–827. https://doi.org/10.1016/S1474-4422(25)00269-8
https://pubmed.ncbi.nlm.nih.gov/40975098/
Migraine Tracker app - Migraine Canada
SNOOP Mnemonic (Courtesy of Dr. Dan James posted in the chat)
Systemic symptoms including fever
Neoplasm history
Neurologic deficit (including decreased consciousness)
Onset is sudden or abrupt
Older age (onset after age 50 years)
Pattern change or recent onset of new headache
Positional headache
Precipitated by sneezing, coughing, or exercise
Papilledema
Progressive headache and atypical presentations
Pregnancy or puerperium
Painful eye with autonomic features
Post-traumatic onset of headache
Pathology of the immune system such as HIV
Painkiller (analgesic) overuse (eg, medication overuse headache) or new drug at onset of headache